Stay updated with breaking news from Programmed Death. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from F. Hoffmann-La Roche Ltd, New data from the phase II CITYSCAPE trial show encouraging results with Roche’s novel anti-TIGIT tiragolumab plus Tecentriq
Investegate announcements from F. Hoffmann-La Roche Ltd, US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
-- Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting -- Approval is based on the Phase III IMpower010 study showing adjuvant ... | October 15, 2021
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant settingApproval is based on the Phase III IMpower010 study showing adjuvant Tecentriq improved disease-free survival
Immuno-Oncology Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027 7Newswire 13 May 2021, 22:51 GMT+10 The research report titled Immuno-Oncology offers comprehensive information on key driving factors, pricing analysis, market growth trends, brand positioning, competitive landscape, product usage and consumer psyche. This report provides an extensive analysis on market segmentation, strategies for prominent players and market overview. The market overview consists of important parameters extracted from different government bodies, indust...